Izalontamab brenitecan shows promising activity in previously treated EGFR mutated NSCLC
Published on 13 October 2026
Dr Alex Spira speaks to ecancer about a global phase I study that evaluates three doses of iza-bren (izalontamab brenitecan), an EGFR and HER3 bispecific antibody drug conjugate, in patients with previously treated EGFR-mutated metastatic NSCLC.
Among 80 patients who had progressed on third-generation EGFR inhibitors, iza-bren achieved an overall response rate of 28.8% and median progression-free survival of 5.4 months.
At the 2.5 mg/kg dose, the overall response rate was 33.3% and median progression-free survival was 6.9 months.
Dr Spira says that grade 3 or higher treatment-related adverse events occurred in 47.5% of patients, most commonly anaemia and neutropenia.
He highlights that the findings support 2.5 mg/kg as the recommended phase III dose, with primary G-CSF prophylaxis helping to manage haematological toxicity.